BRIDGEWATER, N.J. — Amneal Pharmaceuticals has rolled out budesonide capsules 3 mg, a medication for Crohn’s disease.
Amneal said its budesonide capsules are a generic version of Entocort EC from AstraZeneca plc.
The generic product has begun shipping to wholesalers, distributors and direct to the trade, Amneal added.
A steriod medication, budesonide reduces inflammation in the body and is indicated for the treatment of mild to moderate Crohn’s disease as well as ulcerative colitis.
Budesonide and its generic equivalents totaled U.S. sales of $187 million for the 12 months through November 2017, according to IQVIA market data reported by Amneal.
Budesonide is the first product launch of the new year for Amneal Pharmaceuticals. In 2017, the company received 45 ANDA approvals (39 final and 6 tentative) and launched 35 product families—nine of these by its injectables subsidiary Amneal Biosciences.